B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90

Benzinga · 11/10/2025 14:51
B. Riley Securities analyst Mayank Mamtani reiterates Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $80 to $90.